AZTR
Azitra, Inc.
Industry
Biotechnology
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Loading...
Open
0.47
Mkt cap
3.4M
Volume
204K
High
0.48
P/E Ratio
N/A
52-wk high
68.40
Low
0.43
Div yield
N/A
52-wk low
0.43

Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 4:18 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.